Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock. (HyStOON)
Primary Purpose
Septic Shock, Adult
Status
Terminated
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
hydrocortison hemisuccinate
placebo followed by hydrocortisone hemisuccinate
Sponsored by
About this trial
This is an interventional treatment trial for Septic Shock
Eligibility Criteria
Inclusion Criteria:
- age over 18 yrs
- consent obtained
- septic shock (according to international definition)
- patient sedated and submitted to invasive mechanical ventilation
- no need for surgery expected within 24 hours after enrollment
- patient has received at least one dose of large spectrum antibiotics
- superior vena cava catheter in place
- patient carrying a thermodilution device for cardiac output measurement
- stable mean arterial pressure within 65-5 mmHg limits for at least 2 hours;
Exclusion Criteria:
- pregnancy
- age below 18 years
- patient treated with iv continuous epinephrine
- chronic occlusive arteriopathy of the upper limbs
- regular or recent treatment with glibenclamide or glipizide
- regular or recent treatment with steroids
- known surrenal insufficiency
Sites / Locations
- Centre Hospitalier Régional d'Orléans
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
placebo
hydrocortison
Arm Description
10 mL normal saline iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H8, H14 and H20
50 mg hydrocortison iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H12, H18 and H24
Outcomes
Primary Outcome Measures
Vasoreactivity
Secondary Outcome Measures
Full Information
NCT ID
NCT01817153
First Posted
March 20, 2013
Last Updated
February 10, 2020
Sponsor
Centre Hospitalier Régional d'Orléans
1. Study Identification
Unique Protocol Identification Number
NCT01817153
Brief Title
Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock.
Acronym
HyStOON
Official Title
Effect of Intravenous Hydrocortison on Post-ischemic Brachial Artery Dilation and on Thenar Oxygen Saturation in Adult Septic Shock. A Human Placebo-controlled Randomized Study.
Study Type
Interventional
2. Study Status
Record Verification Date
February 2020
Overall Recruitment Status
Terminated
Why Stopped
not enough recruitment
Study Start Date
November 5, 2013 (Actual)
Primary Completion Date
November 5, 2019 (Actual)
Study Completion Date
November 5, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Centre Hospitalier Régional d'Orléans
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main objectives of the study are 1)to examine the immediate (2 hours) and delayed (8 hours) effects of intravenous hydrocortison on macro and microvascular post-ischemic vasoreactivity, in septic shock adult patients; 2) to examine possible correlations between post-ischemic flow-mediated dilation (FMD) of the brachial artery (assessed by ultrasound imaging) and post-ischemic recovery slope of the thenar oxygen saturation (StO2) (assessed by near-infrared spectroscopy).
Detailed Description
Two primary end points, considered as reflecting vasoreactivity will be assessed :
Flow-mediated dilation (FMD) of the brachial artery, measured by ultrasound imaging, expressed in mm or in percentage, will be calculated from artery diameters measured before and after a vascular occlusion test (cuff around arm or forearm).
recovery slope of thenar oxygen saturation (StO2), assessed by near infrared spectroscopy (NIRS), expressed in %/second, will be recorded after the vascular occlusion test.
The two primary end points (FMD and recovery slope of StO2)will be assessed at the following timepoints :
baseline (before first injection of placebo or hydrocortison)
2 hours after first injection of placebo or hydrocortison
2 hours after second injection of placebo or hydrocortison (i.e. 8 hours after first injection)
4 to 6 hours after third injection
4 to 6 hours after fourth injection (optional)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock, Adult
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
10 mL normal saline iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H8, H14 and H20
Arm Title
hydrocortison
Arm Type
Active Comparator
Arm Description
50 mg hydrocortison iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H12, H18 and H24
Intervention Type
Drug
Intervention Name(s)
hydrocortison hemisuccinate
Intervention Type
Drug
Intervention Name(s)
placebo followed by hydrocortisone hemisuccinate
Primary Outcome Measure Information:
Title
Vasoreactivity
Time Frame
every 6 hours over the first 24 hours of intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age over 18 yrs
consent obtained
septic shock (according to international definition)
patient sedated and submitted to invasive mechanical ventilation
no need for surgery expected within 24 hours after enrollment
patient has received at least one dose of large spectrum antibiotics
superior vena cava catheter in place
patient carrying a thermodilution device for cardiac output measurement
stable mean arterial pressure within 65-5 mmHg limits for at least 2 hours;
Exclusion Criteria:
pregnancy
age below 18 years
patient treated with iv continuous epinephrine
chronic occlusive arteriopathy of the upper limbs
regular or recent treatment with glibenclamide or glipizide
regular or recent treatment with steroids
known surrenal insufficiency
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thierry Boulain, MD
Organizational Affiliation
Centre Hospitalier Régional d'Orléans, France
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Hospitalier Régional d'Orléans
City
Orléans
ZIP/Postal Code
45000
Country
France
12. IPD Sharing Statement
Learn more about this trial
Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock.
We'll reach out to this number within 24 hrs